Crucell and US Navy Sign Agreement to Test AdVac®-based Vaccine Against Anthrax and Plague
Like Ebola and Marburg, anthrax and plague are among the so-called 'Category A' agents, which are considered by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to pose a significant risk in the event of use as bioterrorist agents. Category A agents can be easily disseminated or transmitted from person-to-person, result in high rates of mortality, may cause public panic and require special action for public health preparedness.
Crucell is already in the course of developing an Ebola vaccine with the Vaccine Research Center (VRC) of the US National Institutes of Health and the US Army Medical Research Institute for Infectious Diseases (USAMRIID), utilizing adenovirus vector technology and PER.C6® production technology. The same technology will be used for the collaboration with the US Navy on anthrax and plague. Under the terms of the CRADA, Crucell has obtained an option on exclusive commercialization rights to any vaccine that could result from the collaboration.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.